Raymond James Financial Inc. bought a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 481,989 shares of the biopharmaceutical company's stock, valued at approximately $14,508,000. Raymond James Financial Inc. owned approximately 0.31% of TG Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds and other institutional investors have also made changes to their positions in TGTX. Arizona State Retirement System grew its holdings in shares of TG Therapeutics by 0.9% during the fourth quarter. Arizona State Retirement System now owns 42,639 shares of the biopharmaceutical company's stock worth $1,283,000 after buying an additional 364 shares during the last quarter. Proficio Capital Partners LLC purchased a new position in shares of TG Therapeutics during the fourth quarter worth about $306,000. Cookson Peirce & Co. Inc. grew its holdings in shares of TG Therapeutics by 61.7% during the fourth quarter. Cookson Peirce & Co. Inc. now owns 28,081 shares of the biopharmaceutical company's stock worth $845,000 after buying an additional 10,718 shares during the last quarter. Victory Capital Management Inc. grew its holdings in shares of TG Therapeutics by 65.3% during the fourth quarter. Victory Capital Management Inc. now owns 54,034 shares of the biopharmaceutical company's stock worth $1,626,000 after buying an additional 21,355 shares during the last quarter. Finally, Westover Capital Advisors LLC purchased a new position in shares of TG Therapeutics during the fourth quarter worth about $214,000. Institutional investors and hedge funds own 58.58% of the company's stock.
TG Therapeutics Stock Performance
TGTX traded up $1.10 during trading on Friday, reaching $42.99. The company's stock had a trading volume of 4,649,514 shares, compared to its average volume of 2,984,697. The company's fifty day moving average price is $33.17 and its 200-day moving average price is $29.63. TG Therapeutics, Inc. has a 52-week low of $12.93 and a 52-week high of $43.15. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. The company has a market capitalization of $6.75 billion, a price-to-earnings ratio of -429.86 and a beta of 2.30.
TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.08 by $0.07. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The company had revenue of $108.19 million during the quarter, compared to the consensus estimate of $100.67 million. On average, equities analysts forecast that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.
Insider Activity
In related news, CFO Sean A. Power sold 10,021 shares of TG Therapeutics stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $28.53, for a total transaction of $285,899.13. Following the completion of the transaction, the chief financial officer now directly owns 660,611 shares in the company, valued at $18,847,231.83. The trade was a 1.49 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 10.50% of the company's stock.
Wall Street Analyst Weigh In
A number of research firms recently issued reports on TGTX. JPMorgan Chase & Co. raised their price target on TG Therapeutics from $30.00 to $43.00 and gave the stock an "overweight" rating in a report on Monday, November 25th. StockNews.com raised TG Therapeutics from a "sell" rating to a "hold" rating in a report on Tuesday, March 4th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $55.00 price objective on shares of TG Therapeutics in a report on Tuesday, March 4th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat.com, TG Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $40.67.
View Our Latest Stock Report on TG Therapeutics
TG Therapeutics Profile
(
Free Report)
TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
Read More
Before you consider TG Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TG Therapeutics wasn't on the list.
While TG Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
